Defining At-Risk Groups and Optimum Protective Strategies for Invasive Meningococcal Disease
Slide Lecture with Audio
Sponsored by North American Center for Continuing Medical Education, LLC
Faculty
Presenter/Q&A Cohost
Lee Harrison, MD
Professor of Medicine and Epidemiology
Infectious Diseases Epidemiology Research Unit
University of Pittsburgh School of Medicine and Graduate School of Public Health
Pittsburgh, Pennsylvania
Q&A Cohosts
Gary S. Marshall, MD
Professor of Pediatrics
University of Louisville School of Medicine
Louisville, Kentucky
Stanford T. Shulman, MD
Virginia H. Rogers Professor of Pediatric Infectious Diseases
Northwestern University
The Feinberg School of Medicine
Chief, Division of Infectious Diseases
The Children’s Memorial Hospital
Chicago, Illinois
Target Audience
This activity is designed for pediatricians and pediatric nurses
Learning Objectives
After completing this activity, participants should be able to:
- Outline the US burden of meningococcal disease and the populations at greatest risk for invasive disease
- Utilize meningococcal disease epidemiology and active surveillance networks data representing US disease incidence
- Chart N. meningitides serogroups associated with US disease incidence and their cyclical fluctuations
- Discuss the importance of immunologic response to vaccination and duration of protection
- Describe characteristics of current and emerging choices for meningococcal vaccination in patient populations at increased risk for invasive disease
Activity Overview
This on-demand slide lecture with audio is available with HTML slides and the presentation transcript.
To be eligible for documentation of credit, participants must participate in the full educational activity, complete the 10-question online post-test with a score of 70% or better, and complete the evaluation form. After successful completion of the post-test and evaluation form online at www.naccme.com, participants may immediately print their documentation of credit.
There is no fee associated with this activity.
For questions regarding this activity, please call 609-371-1137.
Participants who have successfully competed the live version of this activity are not eligible to receive credit for this enduring material.
Release Date: March 16, 2010
Expiration Date: March 16, 2011
Estimated Time to Complete: 1 hour
Hardware/Software Requirements
All educational activities are accessible via a computer with 650 MHz PC, 128 MB RAM, Windows or MAC operating system, Internet Explorer, Netscape, or Safari browsers. Windows Media Player, sound card, and speakers are required for streamed audio. Flash Player, sound card, and speakers are required for video programs. A PDF reader is required for print publications. Please direct technical questions to webmaster@naccme.com.
CME Accreditation
North American Center for Continuing Medical Education, LLC (NACCME) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
NACCME designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
CNE Accreditation
North American Center for Continuing Medical Education, LLC (NACCME) is an approved provider of continuing nursing education by the Pennsylvania State Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation.
This continuing nursing education activity was approved for 1 contact hour.
Provider approved by the California Board of Registered Nursing, Provider #13255 for 1 contact hour.
Independent Clinical Reviewer: C. Buddy Creech, MD, MPH, Assistant Professor of Medicine, Pediatric Infectious Diseases and Vanderbilt Vaccine Research Program, Co-Director, Pediatric Infectious Diseases Fellowship Program, Vanderbilt University School of Medicine and the Monroe Carell, Jr. Children’s Hospital at Vanderbilt, Nashville, Tennessee
Independent Nurse Clinical Reviewer: Nancy M. Hutchinson, RN, MSN, CIC, Nurse Epidemiologist, Infection Control Program, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio
Planning Committee
The planning committee comprises Lee Harrison, MD, Gary S. Marshall, MD, Stanford T. Shulman, MD, C. Buddy Creech, MD, MPH, Nancy M. Hutchinson, RN, MSN, CIC; and Randy Robbin, Rosemary Hodgson, Emilie McCardell, John Savage, and William Kormos, NACCME.
Financial Disclosure and Conflicts of Interest
According to the disclosure policy of NACCME, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity. All relevant conflicts of interest that are indentified are reviewed for potential conflicts of interest. If a conflict is identified, it is the responsibility of NACCME to initiate a mechanism to resolve the conflict(s). The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.
All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.
The faculty has reported the following:
Dr. Harrison: Grant/Research Support—Sanofi Pasteur; Consultant—GSK, Merck & Co, Novartis, Sanofi Pasteur, Wyeth Pharmaceuticals; Scientific Advisor/Advisory Board—GSK, Merck & Co, Novartis, Sanofi Pasteur, Wyeth Pharmaceuticals; Promotional Speakers’ Bureau—Novartis, Sanofi Pasteur
Dr. Marshall: Grant/Research Support—GSK, Merck & Co, Novartis, Sanofi Pasteur; Consultant—GSK, Merck & Co, Novartis; Promotional Speakers’ Bureau—Sanofi Pasteur
Dr. Shulman: Scientific Advisor—Merck & Co, Novartis
Dr. Creech: Grant/Research Support—Cubist Pharmaceuticals, Merck & Co
Ms. Hutchinson has disclosed no relevant financial relationships with any commercial interests.
Mr. Robbin, Ms. Hodgson, Ms. McCardell, Mr. Savage, and Mr. Kormos have disclosed no relevant financial relationships with any commercial interests.
NACCME requires faculty to inform participants whenever off-label/unapproved uses of drugs and/or devices are discussed in their presentations.
The faculty has disclosed that MCV4, HibMenCY-TT, MenACWY-CRM, universal serogroup B vaccines in development will be discussed.
This continuing medical education activity includes medication brand names for participant clarity purposes only, due to like-named chemicals. No product promotion or recommendations should be inferred.
Privacy Policy
NACCME protects the privacy of personal and other information regarding participants, educational partners, and joint sponsors. NACCME and our joint sponsors will not release personally identifiable information to a third party without the individual’s consent, except such information as is required for reporting purposes to the appropriate reporting agency.
NACCME maintains physical, electronic, and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.
Copyright ©2010 by North American Center for Continuing Medical Education, LLC. All rights reserved. No part of this accredited continuing medical education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from North American Center for Continuing Medical Education.
Grant Support
Supported by an independent educational grant from Novartis
